Oncodesign: no reaction to announcements











Photo credit © Reuters


(Boursier.com) — Oncodesign remained stable at 14.30 euros on Friday, while the pharmaceutical group Servier and Oncodesign Precision Medicine (OPM), a subsidiary ofOncodesignhave entered into a collaborative research agreement, named “STarT Pancreas”, for the identification and validation of new therapeutic targets aimed at the development of new treatments for pancreatic ductal adenocarcinoma (PDAC).
For a period of 3 years, the agreement between Oncodesign Precision Medicine and Servier provides for two stages:
– the initial co-development which will allow the identification of targets from the generation of data based on the OncoSNIPE clinical trial;
– experimental validation of discoveries resulting from artificial intelligence;

Servier benefits from the option of initiating alone, or within the framework of a new partnership with Oncodesign Precision Medicine, a drug discovery program for each of the targets selected by Servier.

Under the terms of the agreement, Servier and OPM (through its OncoSNIPE program) will be in charge of clinical research activities. Servier will finance the associated research costs. Funding for the target identification program will be provided by OPM and Servier.

Exclusive Option

Servier has an exclusive option of an exclusive worldwide license on the results of the program, which can be exercised as soon as the targets are identified. If Servier does not exercise the option, OPM recovers an exclusive option on an exclusive license on certain categories of targets. OPM will receive an initial payment of 0.5 million euros and a second payment of 0.5 ME, no later than December 31, 2024, subject to the achievement of certain objectives, as well as other milestone payments until validation of entry into Phase 1 of the drug candidate(s).

Recall that pancreatic cancer is considered one of the most difficult cancers to treat effectively, due to its insidious symptoms and high degree of malignancy resulting in a high mortality rate. In 2018 in France, pancreatic cancer was the 9th most common cancer in men and the 7th most common cancer in women. The number of new cases in France is estimated at 14,184 per year. Treatment needs are great, because the incidence of pancreatic cancer is increasing year by year.


©2022 Boursier.com






Source link -87